Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab beta maintenance in relapsed/refractory osteosarcoma
NCT05558280Phase 2Suspended
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Dinutuximab beta in osteosarcoma (OS). Started Nov 2023; status: suspended.
02
Drugs
Dinutuximab beta
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05558280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558280.